SeaStar Medical Holding Corp
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
ICU$1.90-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)
Condensed Consolidated Statements of Changes in Stockholders' Deficit
| Stockholders' Deficit (unaudited) | |||||
|---|---|---|---|---|---|
| Common Shares | |||||
| Shares | Amount | Additional Paid-In Capital | Accumulated Deficit | Total Stockholders' Deficit | |
| Balance as of December 31, 2023 | 2,016,078 | $1 | $100,863 | $(114,734) | $(13,870) |
| Issuance of shares - conversion of convertible notes | 507,912 | — | 9,389 | — | 9,389 |
| Issuance of shares - exercise of warrants | 352,074 | — | 3,959 | — | 3,959 |
| Issuance of shares - equity offerings, net of issuance costs | 252,182 | — | 8,309 | — | 8,309 |
| Stock-based compensation | — | — | 434 | — | 434 |
| Net loss | — | — | — | (12,697) | (12,697) |
| Balance as of March 31, 2024 | 3,128,246 | $1 | $122,954 | $(127,431) | $(4,476) |
| Issuance of shares - conversion of convertible notes | 92,858 | — | 826 | — | 826 |
| Issuance costs - registration of previously issued warrants | — | — | (56) | — | (56) |
| Stock-based compensation | — | — | 41 | — | 41 |
| Net loss | — | — | — | (3,236) | (3,236) |
| Balance as of June 30, 2024 | 3,221,104 | $1 | $123,765 | $(130,667) | $(6,901) |
| Balance as of December 31, 2022 | 507,987 | $1 | $67,739 | $(88,502) | $(20,762) |
| Issuance of shares - equity line of credit | 15,120 | — | 1,108 | — | 1,108 |
| Issuance of shares - commitment fee for equity line of credit | 8,754 | — | 1,000 | — | 1,000 |
| Issuance of shares - prepaid forward contracts | — | — | 1,870 | — | 1,870 |
| Stock-based compensation | — | — | 505 | — | 505 |
| Net loss | — | — | — | (7,096) | (7,096) |
| Balance as of March 31, 2023 | 531,861 | $1 | $72,222 | $(95,598) | $(23,375) |
| Issuance of shares - equity line of credit | 1,080 | — | 55 | — | 55 |
| Issuance of shares - conversion of convertible notes | 123,527 | — | 1,936 | — | 1,936 |
| Issuance of shares - vesting of RSUs | 6,136 | — | — | — | — |
| Issuance of shares - prepaid forward contracts | 43,879 | — | — | — | — |
| Forward Purchase Agreement Derivative Liability | — | — | 11,519 | — | 11,519 |
| Stock-based compensation | 18,367 | — | 555 | — | 555 |
| Net loss | — | — | — | (2,447) | (2,447) |
| Balance as of June 30, 2023 | 724,850 | $1 | $86,287 | $(98,045) | $(11,757) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.